ORLANDO, Fla., July 27 /PRNewswire-FirstCall/ -- Telzuit Medical Technologies, Inc. announced today that it has successfully tested the functionality of the STATPATCH Wireless Holter Monitor and that the product is currently in physician testing with healthy volunteers. The testing is expected to last for several weeks, followed by the product rollout in Florida this year. The successful testing and physician release is the culmination of over five years of research and development in various areas of ambulatory cardiac monitoring and paves the way for the release of the Company's other wireless medical devices. The patent pending STATPATCH Wireless Heart Monitor is already FDA approved, and the Company expects to make additional FDA submissions over the next twelve months for other medical devices.
Warren Stowell, CEO of Telzuit, commented, "Today marks the beginning of the next phase of our product roll out. With the STATPATCH in the final stage of patient testing, we are very excited about the imminent release of our first product."
About Telzuit Medical Technologies, Inc.
Telzuit Medical Technologies, Inc. is dedicated to providing advanced mobile medicine for people worldwide. The first step in this mission will initially take the form of our state-of-the-art, FDA approved, STATPATCH Wireless Heart Monitor. This is a full 12-lead, completely wireless, Holter monitor, which is new to the marketplace. Telzuit is also building its own dedicated intranet as a platform to handle several of the products it will be releasing, including its initial product, the STATPATCH Wireless Heart Monitor System. Telzuit is based in Orlando, Florida. For more information on the company, its business model, and its products can be found on its website: http://www.telzuit.com.
Forward Looking Statement: Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties, including the effect of changing economic conditions, competition within the health products industry, customer acceptance of products, and other risks and uncertainties. Such forward-looking statements are not guarantees of performance, and Telzuit results could differ materially from those contained in such statements. These forward-looking statements speak only as of the date of this release, and Telzuit undertake no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.
Contact: Telzuit Medical Technologies, Inc. James Tolan Co-Founder, Telzuit Medical Technologies, Inc 407-354-1222
Telzuit Medical Technologies, Inc.CONTACT: James Tolan, Co-Founder, Telzuit Medical Technologies, Inc.,+1-407-354-1222
Web site: http://www.telzuit.com/